Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("BAXEVANIS, Constantin N")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 19 of 19

  • Page / 1
Export

Selection :

  • and

Therapeutic cancer vaccines: a long and winding road to successBAXEVANIS, Constantin N; PAPAMICHAIL, Michael; PEREZ, Sonia A et al.Expert review of vaccines. 2014, Vol 13, Num 1, pp 131-144, issn 1476-0584, 14 p.Article

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant miceGRITZAPIS, Angelos D; VOUTSAS, Ioannis F; BAXEVANIS, Constantin N et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 3, pp 397-407, issn 0340-7004, 11 p.Article

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3+CD56+ (natural killer T) lymphocytesBAXEVANIS, Constantin N; GRITZAPIS, Angelos D; TSITSILONIS, Ourania E et al.International journal of cancer. 2002, Vol 98, Num 6, pp 864-872, issn 0020-7136Article

Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragmentBELIMEZI, Maria M; PAPANASTASSIOU, Danai; MERKOURI, Efrossini et al.Cancer immunology and immunotherapy. 2006, Vol 55, Num 9, pp 1091-1099, issn 0340-7004, 9 p.Article

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapyBAXEVANIS, Constantin N; SOTIROPOULOU, Panagiota A; SOTIRIADOU, Nectaria N et al.Cancer immunology and immunotherapy. 2004, Vol 53, Num 3, pp 166-175, issn 0340-7004, 10 p.Conference Paper

Peptide Vaccination Breaks Tolerance to HER-2/neu by Generating Vaccine-Specific FasL+ CD4+ T Cells: First Evidence for Intratumor Apoptotic Regulatory T CellsGRITZAPIS, Angelos D; VOUTSAS, Loannis F; LEKKA, Eftychia et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 7, pp 2686-2696, issn 0008-5472, 11 p.Article

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapyLEKKA, Eftychia; GRITZAPIS, Angelos D; PEREZ, Sonia A et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 5, pp 715-727, issn 0340-7004, 13 p.Article

Efficacy of novel culture environments on the ex vivo expansion kinetics of cord blood progenitor cellsCACOULIOS, Nike T; GRITZAPIS, Angelos D; TSITSILONIS, Athanasios E et al.Haematologica (Roma). 2002, Vol 87, Num 3, pp 320-321, issn 0390-6078Article

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-key moiety of the invariant chainVOUTSAS, Ioannis F; GRITZAPIS, Angelos D; MAHAIRA, Louisa G et al.International journal of cancer. 2007, Vol 121, Num 9, pp 2031-2041, issn 0020-7136, 11 p.Article

In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the γ-chain from Fc(ε) RIMAMALAKI, Avgi; GRITZAPIS, Angelos D; KRETSOVALI, Androniki et al.Cancer immunology and immunotherapy. 2003, Vol 52, Num 8, pp 513-522, issn 0340-7004, 10 p.Article

Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumorsSOTIROPOULOU, Panagiota A; PEREZ, Sonia A; VOELTER, Volfgang et al.Cancer immunology and immunotherapy. 2003, Vol 52, Num 12, pp 771-779, issn 0340-7004, 9 p.Article

HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor propertiesGRITZAPIS, Angelos D; FRIDMAN, Arthur; PEREZ, Sonia A et al.Vaccine. 2010, Vol 28, Num 1, pp 162-170, issn 0264-410X, 9 p.Article

Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assayGRITZAPIS, Angelos D; BAXEVANIS, Constantin N; MISSITZIS, Ioannis et al.Breast cancer research and treatment. 2003, Vol 80, Num 1, pp 1-13, issn 0167-6806, 13 p.Article

Increased frequency of CD4+ cells expressing CD161 in cancer patientsILIOPOULOU, Eleni G; KARAMOUZIS, Michalis V; MISSITZIS, Ioannis et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 6901-6909, issn 1078-0432, 9 p.Article

HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+T cell clonesPEREZ, Sonia A; SOTIROPOULOU, Panagiota A; SOTIRIADOU, Nectaria N et al.Cancer immunology and immunotherapy. 2002, Vol 50, Num 11, pp 615-624, issn 0340-7004Article

A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survivalPEREZ, Sonia A; MAHAIRA, Louisa G; DEMIRTZOGLOU, Fillio J et al.Blood. 2005, Vol 106, Num 1, pp 158-166, issn 0006-4971, 9 p.Article

A novel myeloid-like NK cell progenitor in human umbilical cord bloodPEREZ, Sonia A; SOTIROPOULOU, Panagiota A; GKIKA, Dimitra G et al.Blood. 2003, Vol 101, Num 9, pp 3444-3450, issn 0006-4971, 7 p.Article

Results from a Phase I Clinical Study of the Novel Li-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate CancerPEREZ, Sonia A; KATLLINTERIS, Nikoletta L; BISIAS, Stratos et al.Clinical cancer research (Print). 2010, Vol 16, Num 13, pp 3495-3506, issn 1078-0432, 12 p.Article

CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and her-negative advanced-stage breast cancer patientsPEREZ, Sonia A; KARAMOUZIS, Michael V; PAPAMICHAIL, Michael et al.Clinical cancer research. 2007, Vol 13, Num 9, pp 2714-2721, issn 1078-0432, 8 p.Article

  • Page / 1